| Name | Title | Contact Details |
|---|
San Diego FC is a Major League Soccer (MLS) expansion team set to begin play in 2025. Owned by Sir Mohamed Mansour through his family office, Man Capital, the club focuses on social impact, environmental sustainability, and youth development. It operates under the Right to Dream model, a globally recognized soccer academy system that emphasizes holistic athlete development and community engagement. The team will compete in MLS, with home games at Snapdragon Stadium. San Diego FC also features the Right to Dream Academy, which provides free education, housing, and soccer training to young athletes. This academy aims to foster athletic development, academic excellence, and personal growth, mirroring existing facilities in Ghana, Egypt, and Denmark. Additionally, the club engages in community programs that promote diversity and inclusion, targeting local residents and youth athletes from underserved communities. The ownership structure reflects a partnership between Mansour’s Man Capital and the Sycuan Tribe, blending global sports investment with local heritage.
ClearView Healthcare Partners is a global strategy consulting firm focused on the life sciences sector. Founded in 2007 in Boston, the company provides strategic advice across various therapeutic areas and technologies. ClearView combines scientific expertise with analytical rigor to help clients develop growth strategies at the product, franchise, and corporate levels. The firm operates globally, with offices in North America, including Boston, New York, and San Francisco, and has expanded into Europe with locations in London and Zurich. ClearView offers a range of services, including market analysis, launch strategy development, pricing strategies, and advanced analytics, tailored to support pharmaceutical, biotechnology, medical device, and diagnostics companies, as well as investors in the life sciences sector. ClearView is guided by principles of clarity, quality, and collaboration, ensuring high-quality solutions developed in partnership with clients. The company fosters an intellectually stimulating environment and attracts motivated individuals through a competitive hiring process.
Mechanics is a Ohio-based community bank that offers services including personal and business banking, trust, mortgages and loans for individuals and businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".